17.45% to Target, Piper Jaffray Reconfirms “Buy” Rating for Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock; 10 Bullish Analysts Covering Open Text (OTEX)

June 16, 2018 - By Vivian Currie

Open Text Corporation (NASDAQ:OTEX) Logo

They currently have a $48.0000 target price on Biohaven Pharmaceutical Holding Co Ltd (BHVN). Piper Jaffray’s target would suggest a potential upside of 17.45% from the company’s last stock price. This was revealed in analysts report on Friday morning.

Among 12 analysts covering OpenText Corporation (NASDAQ:OTEX), 10 have Buy rating, 1 Sell and 1 Hold. Therefore 83% are positive. OpenText Corporation had 26 analyst reports since July 30, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of OTEX in report on Thursday, February 1 with “Buy” rating. BMO Capital Markets upgraded Open Text Corporation (NASDAQ:OTEX) on Tuesday, September 13 to “Outperform” rating. RBC Capital Markets maintained Open Text Corporation (NASDAQ:OTEX) on Wednesday, July 12 with “Buy” rating. Citigroup initiated Open Text Corporation (NASDAQ:OTEX) rating on Thursday, February 16. Citigroup has “Neutral” rating and $36 target. The company was reinitiated on Tuesday, January 24 by Barclays Capital. Barclays Capital maintained the stock with “Overweight” rating in Friday, August 4 report. BMO Capital Markets maintained the shares of OTEX in report on Thursday, August 3 with “Buy” rating. BMO Capital Markets maintained it with “Buy” rating and $42.0 target in Thursday, February 1 report. The rating was downgraded by Macquarie Research to “Sell” on Wednesday, November 22. The rating was maintained by Scotia Capital with “Buy” on Thursday, February 1. See Open Text Corporation (NASDAQ:OTEX) latest ratings:

01/02/2018 Broker: Scotia Capital Rating: Buy New Target: $45.0 Maintain
01/02/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $44 New Target: $46 Maintain
01/02/2018 Broker: MUFG Securities Americas Inc Rating: Buy New Target: $50.0
01/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $46.0 Maintain
01/02/2018 Broker: BMO Capital Markets Rating: Buy New Target: $42.0 Maintain

Open Text Corporation provides a suite of software services and products that assist organizations in finding, utilizing, and sharing business information from various devices. The company has market cap of $9.61 billion. The firm offers content solutions that provide content and records management, archiving, and email management and capture solutions, as well as Core, a software as a service based multi-tenant cloud solution; business process management for analyzing, automating, monitoring, and optimizing structured business processes; and customer experience management products, which offer Web content management, digital asset management, customer communications management, social software, and portal. It has a 50.1 P/E ratio. The Company’s products also include business network solutions comprising business-to-business integration, fax solutions, and secure messaging; analytics solutions, including embedded reporting and visualization, and big data analysis; and discovery solutions consisting of search, semantic navigation, and auto classification, as well as InfoFusion to deal with the issue of ‘information silosÂ’ resulting from disconnected information sources across the enterprise.

More news for Open Text Corporation (NASDAQ:OTEX) were recently published by: Nasdaq.com, which released: “Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open …” on June 04, 2018. Prnewswire.com‘s article titled: “The OpenText Business Network Powers 23 Of Gartner’s Top 25 Supply Chains” and published on June 08, 2018 is yet another important article.

The stock decreased 0.14% or $0.05 during the last trading session, reaching $35.92. About 460,510 shares traded. Open Text Corporation (NASDAQ:OTEX) has risen 6.83% since June 16, 2017 and is uptrending. It has underperformed by 5.74% the S&P500. Some Historical OTEX News: ; 17/04/2018 – Open Text Closes Above 50-Day Moving Average: Technicals; 30/05/2018 – OPEN TEXT -AMENDMENT OF TERM LOAN INCREASES AMOUNT TO US$1 BLN, EXTENDS MATURITY DATE TO 2025, REDUCES INTEREST RATE MARGIN BY 25 BASIS POINTS; 30/05/2018 – OPENTEXT REPORTS REPRICING & AMENDMENT OF CREDIT LINES; 17/04/2018 – 13D CONF: ROBBINS SAYS OPEN TEXT MISPRICED, INEXPENSIVE COMPANY; 09/05/2018 – OPENTEXT BOOSTS QTR DIV TO 15.18C/SHR FROM 13.2C, EST. 15.5C; 02/04/2018 MADHU RANGANATHAN JOINS OPENTEXT AS CHIEF FINANCIAL OFFICER; 23/05/2018 – S&PGR Rates Open Text’s Prpsd US$1B Term Loan ‘BBB-‘ (RR: ‘1’); 09/05/2018 – Open Text 3Q Rev $685.9M; 30/05/2018 – OPENTEXT TERM LOAN INCREASED TO $1B, MATURITY DATE TO 2025; 09/05/2018 – OPEN TEXT CORP OTEX.TO – ANNOUNCING A 15% INCREASE TO QUARTERLY CASH DIVIDEND TO $0.1518 PER SHARE

Among 7 analysts covering Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Biohaven Pharmaceutical Holding Company Ltd. Common Shares has $54.0 highest and $30.0 lowest target. $38.43’s average target is -5.97% below currents $40.87 stock price. Biohaven Pharmaceutical Holding Company Ltd. Common Shares had 22 analyst reports since May 30, 2017 according to SRatingsIntel. The stock of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) earned “Buy” rating by Piper Jaffray on Friday, June 8. The firm has “Buy” rating by Piper Jaffray given on Monday, October 2. Needham maintained it with “Buy” rating and $30.0 target in Tuesday, August 15 report. The firm has “Buy” rating by Needham given on Monday, June 19. The firm has “Buy” rating by Piper Jaffray given on Tuesday, May 30. The rating was maintained by Canaccord Genuity on Monday, March 26 with “Buy”. The rating was downgraded by Barclays Capital on Thursday, April 5 to “Equal-Weight”. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, September 12 report. The stock has “Buy” rating by Piper Jaffray on Monday, December 11. The firm has “Overweight” rating given on Tuesday, October 3 by Morgan Stanley.

The stock increased 3.08% or $1.22 during the last trading session, reaching $40.87. About 3.21 million shares traded or 329.05% up from the average. Biohaven Pharmaceutical Holding Company Ltd. (BHVN) has risen 50.20% since June 16, 2017 and is uptrending. It has outperformed by 37.63% the S&P500. Some Historical BHVN News: 09/05/2018 – Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS); 06/03/2018 – Biohaven Enrolls First Patient in Phase 3 Clinical Trial to Evaluate Rimegepant Zydis ODT in the Acute Treatment of Migraine; 09/05/2018 – BIOHAVEN INITIATES EXPANDED ACCESS PROGRAM FOR SUBLINGUAL BHV-0223 ZYDIS ORALLY DISSOLVING TABLETS FOR PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS; 07/03/2018 – Biohaven Pharmaceutical Holding Closes Below 50-Day Average; 15/05/2018 – Biohaven Pharma 1Q Loss/Shr $2.32; 14/03/2018 – Biohaven Pharmaceutical Holding Closes Below 200-Day MA; 15/05/2018 – Biohaven Pharma 1Q Loss $85.5M; 30/04/2018 – Biohaven Pharmaceutical Holding Closes Above 200-D-MA; 19/04/2018 – Biohaven Pharmaceutical Holding Presenting at Conference Apr 23; 06/03/2018 – Biohaven Pharma 4Q Loss/Shr 75c

More recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 12, 2018. Also Prnewswire.com published the news titled: “Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region” on June 13, 2018. Prnewswire.com‘s news article titled: “Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor …” with publication date: June 05, 2018 was also an interesting one.

Analysts await Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to report earnings on August, 13. They expect $-0.99 earnings per share, up 44.38% or $0.79 from last year’s $-1.78 per share. After $-2.32 actual earnings per share reported by Biohaven Pharmaceutical Holding Company Ltd. for the previous quarter, Wall Street now forecasts -57.33% EPS growth.

Open Text Corporation (NASDAQ:OTEX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Vivian Currie

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: